Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial.

By H. Dargie. The Lancet, 2001

1,746 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Task Force on Sudden Cardiac Death of the European Society of Cardiology. (2001, background): “Recently the CAPRICORN trial in post MI patients with left ventricular dysfunction (EF 40%) demonstrated a beneficial effect of carvedilol on total mortality and a trend toward reduction in SCD([184]).”
Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. (2007, result): “Nonetheless, the relative mortality risk reductions associated with -blocker adherence in our study were generally consistent in magnitude with those observed in randomized clinical trials comparing -blockers to placebo.(26,27) While less than 3.”
2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. (2014, methodology): “Dargie, 2001 11356434 (99) Outcomes of carvedilol in AMI with LV dysfunction Multicenter randomized PC controlled 1,959 Carvedilol 975 PC 984 AMI with LVEF≤40%, use of ACE inhibitors <18 y, use of diuretics or inotropes 6.”